Skip to main content
Premium Trial:

Request an Annual Quote

Natera Sells Evercord Cord Blood Banking Business to CBR

NEW YORK – Natera is selling its Evercord cord blood and tissue banking business to CBR (Cord Blood Registry), a California Cryobank Life Sciences company, the firms said today.

"This divestiture will allow Natera to focus squarely on its core genetic testing business in reproductive health, oncology, and organ transplantation," Natera CEO Steve Chapman said in a statement.

"We look forward to safeguarding these newborn stem cells and allowing the Evercord families to take advantage of future advances in cellular therapies and regenerative medicine," said CCLS CEO Richard Jennings in a statement.

Natera launched the Evercord business in 2017, hoping it would enable it to offer newborn whole-genome screening eventually. The service allows parents to collect and store cord blood and tissue from their newborns and retrieve them later, if needed, for therapeutic use. Last year, Natera said that uptake of the service had been slower than anticipated.

CBR said it will work closely with Natera to ensure a smooth transition for customers and ordering clinics.

Financial details of the sale were not disclosed.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.